MinePath is the only among the three methodologies that identifies as discriminant the ATM → CHEK2 relation, with CHEK2 to be considered as a susceptibility gene for inherited BrCa, also related with the mutation status of the well-known BrCa susceptibility genes BRCA1 and BRCA2 [87]. This evidence concerns the gene CHEK2 and invasive breast carcinoma.